AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
4.580
+0.310 (7.26%)
At close: Aug 13, 2025, 4:00 PM
4.425
-0.155 (-3.38%)
Pre-market: Aug 14, 2025, 9:21 AM EDT
AbCellera Biologics Employees
AbCellera Biologics had 596 employees as of December 31, 2024. The number of employees increased by 10 or 1.71% compared to the previous year.
Employees
596
Change (1Y)
10
Growth (1Y)
1.71%
Revenue / Employee
$55,161
Profits / Employee
-$277,961
Market Cap
1.37B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ABCL News
- 1 day ago - AbCellera to Participate at Upcoming Investor Conferences in September - Business Wire
- 6 days ago - AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms - Business Wire
- 5 weeks ago - AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire
- 2 months ago - AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 - Business Wire
- 3 months ago - AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause - Business Wire
- 3 months ago - AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit - Business Wire
- 3 months ago - AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting - Business Wire